Company
VERO Biotech
Innovation in the Delivery of Inhaled Nitric Oxide
Also known as Vero Biotech, Inc.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Customers
- customers in the acute care hospital setting
- Legal name
- Vero Biotech, Inc.
- vero-biotech.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 20 September 2026
About
VERO Biotech is an emerging biotechnology company focused on the design, development, and commercialization of next generation inhaled nitric oxide (iNO) delivery systems to address unmet medical needs of patients with cardiopulmonary conditions.
Funding snapshot
- Total raised
- $95MSum of rounds, as of 2026-09-20Source (opens in a new tab)
- Latest round
- Debt, $65M2024-02-07
Funding rounds
- Debt
- $65M2024-02-07, Company stated
- Round, 2023
- $30M2023-01-11, Company stated
- Round, 2021
- $27.3M2021-12-08, SEC form D sold, 5 investors
- Round, 2017
- $29.9M2017-09-01, SEC form D sold, 31 investors
- Round, 2013
- $14.7M2013-09-20, SEC form D sold, 41 investors
- Round, 2011
- $8M2011-02-17, SEC form D sold, 21 investors
- Round, 2009
- $2.1M2009-09-02, SEC form D sold, 18 investors
Products
- Hardware
- GENOSYL Delivery System
Loading relationship preview